ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers.
0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed
13.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 205 citations in OpenAlex.
- Trial
- Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4CNS oncology · 2018Trial
- Tryptophan metabolism in tumor microenvironment and therapeutic implications.Journal of advanced research · 2026Review
- Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- The Double-Edged Sword: How Radiotherapy Shapes the Tumor Immune Microenvironment to Modulate Responses to Checkpoint Inhibitors.International journal of molecular sciences · 2026Review
- Review
- Metabolic modulation of immune cell function: mechanisms and therapeutic implications in cancer immunotherapy.Oncogenesis · 2026Review
- Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026.Cells · 2026Review
- The promise of immunotherapy for central nervous system tumours.Nature reviews. Immunology · 2026Review
- Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy.Acta pharmaceutica Sinica. B · 2026Review
- Indoleamine 2,3-dioxygenase 1 inhibition reverses cancer-associated fibroblast-mediated immunosuppression in high-grade serous ovarian cancer.FEBS open bio · 2026Article
- Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Improving Immune Checkpoint Therapy in the Tumor Microenvironment by Targeting T Cell Metabolism.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies.ImmunoTargets and therapy · 2026Review
- Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion.Signal transduction and targeted therapy · 2026Review
- Nanomaterials Reshaping Tumor Metabolism: A New Frontier to Overcome T Cell Exhaustion.International journal of nanomedicine · 2026Review
- Metabolic reprogramming and immune evasion interaction in the tumor microenvironment promote tumor progression.Frontiers in oncology · 2026Review
- Multiple radiations and its effect on biological system - a review onAnnals of medicine · 2025Review
- The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy.Journal of experimental & clinical cancer research : CR · 2025Review
- Current strategies and novel immunotherapeutic approaches for overcoming immune resistance in glioblastoma.Discover oncology · 2025Review
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 2 countries.
Erik LadomerskyDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Lijie ZhaiDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Alicia LenzenDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Kristen L LauingDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Jun QianDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Denise M ScholtensDepartment of Preventive Medicine-Biostatistics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Galina GritsinaDepartment of Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Xuebing SunBeiGene, Zhong-Guan-Cun Life Science Park, Changping District, Beijing, China.
Ye LiuBeiGene, Zhong-Guan-Cun Life Science Park, Changping District, Beijing, China.
Fenglong YuBeiGene, Zhong-Guan-Cun Life Science Park, Changping District, Beijing, China.
Wenfeng GongBeiGene, Zhong-Guan-Cun Life Science Park, Changping District, Beijing, China.
Yong LiuBeiGene, Zhong-Guan-Cun Life Science Park, Changping District, Beijing, China.
Beibei JiangBeiGene, Zhong-Guan-Cun Life Science Park, Changping District, Beijing, China.
Tristin TangBeiGene, Zhong-Guan-Cun Life Science Park, Changping District, Beijing, China.
Ricky PatelRosalind Franklin University of Medicine and Science, North Chicago, Illinois.
Leonidas C PlataniasDepartment of Medicine-Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
C David JamesDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Roger StuppDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Rimas V LukasRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
David C BinderDepartment of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.
Derek A WainwrightDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Derekwainwright@northwestern.edu.
Northwestern University · USMedigene (Germany) · DERosalind Franklin University of Medicine and Science · USUniversity of Colorado Denver · US
Funding
Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9MTRAINING PROGRAM IN SIGNAL TRANSDUCTION AND CANCERT32CA070085 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1997 to 2026
$5.7MNorthwestern University Clinical and Translational Science Institute (NUCATS)TL1TR001423 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCCOLLEY, SUSANNA A · 2015 to 2023
$5.0MIDO1 and Immunotolerance in GlioblastomaR01NS097851 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHILTZ, GARY E, WAINWRIGHT, DEREK ALAN · 2016 to 2025
$4.6MThe interaction of IDO and Tregs Leads to Immunosuppression in GliomaR00NS082381 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2014 to 2016
$735kThe interaction of IDO and Tregs Leads to Immunosuppression in GliomaK99NS082381 · NINDS · UNIVERSITY OF CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2013 to 2014
$173kThe role of IDO and Th17 in an experimental mouse model of gliomaF32NS073366 · NINDS · UNIVERSITY OF CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2011 to 2012
$86kNCATS NIH HHS TL1 TR001423NCI NIH HHS P30 CA060553NCI NIH HHS T32 CA070085NINDS NIH HHS F32 NS073366NINDS NIH HHS K99 NS082381NINDS NIH HHS R00 NS082381NINDS NIH HHS R01 NS097851
Abstract
PubMed holds no abstract for this paper.
Indexed as
Radiation, IonizingAnimalsAntineoplastic Agents, ImmunologicalCell Line, TumorCombined Modality TherapyDisease Models, AnimalDrug SynergismEnergy MetabolismEnzyme ActivationEnzyme InhibitorsGlioblastomaHumansIndoleamine-Pyrrole 2,3,-DioxygenaseMaleMiceMice, KnockoutAntineoplastic Agents, ImmunologicalEnzyme InhibitorsIDO1 protein, mouseIndoleamine-Pyrrole 2,3,-DioxygenaseProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.